Anthony J. Polverino - 31 Aug 2021 Form 4 Insider Report for Zymeworks Inc.

Role: Chief Scientific Officer
Signature: /s/ Daniel Dex, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 31 Aug 2021
Net transactions value: +$73,500
Form type: 4
Filing time: 02 Sep 2021, 20:00:19 UTC
Previous filing: 08 Jul 2021
Next filing: 10 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZYME	Common Shares	Options Exercise	$73,500	+4,900	+16%	$15.00^*	36,333	31 Aug 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZYME	Stock Option (Right to Buy)	Options Exercise	$0	-4,900	-5.9%	$0.000000	77,600	31 Aug 2021	Common Shares	4,900	$15.00	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date of December 12, 2018, and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.